| abstract |
A hydroxy diphenyl urea sulphonamide derivative or a pharmaceutically acceptable salt thereof has the formula (I) wherein: each Rb is independently hydrogen, NR6NR7, OH, ORa, or optionally substituted alkyl, aryl, arylalkyl, arylalkenyl; cycloalkyl, cycloalkylalkyl, heteroaryl, heteroarylalkyl, heterorarylalkenyl, heterocyclic, heterocyclic-alkyl, or a heterocyclic-alkenyl or the two Rb substituents join to form either an optionally unsaturated 3-10 membered cycloalkyl ring or a 3-10 membered heterocyclic ring containing, independently, 1 to 3 NRa, O, S, SO, or SO2 moieties; each R1 is independently hydrogen, halogen, nitro, cyano, alkyl, haloalkyl, alkenyl, alkoxy, haloalkoxy, azide, S(O)tR4, (CR8R8)qS(O)tR4, hydroxy, hydroxyalkyl, aryl, arylalkyl, arylalkenyl, aryloxy, arylalkyloxy, heteroaryl, heteroarylalkyl, heteroarylalkenyl, heteroaryl alkyloxy, heterocyclic, heterocyclic-alkyl, heterocyclic-alkyloxy, heterocyclic-alkenyl, (CR8R8)qNR4R5, (CR8R8)qC(O)NR4R5, alkenyl-C(O)NR4R5, (CR8R8)qC(O)NR4R10, S(O)3R8, (CR8R8)qC(O)R11, alkenylC(O)R11, alkenylC(O)OR11, (CR8R8)qC(O)OR11, (CR8R8)qOC(O)R11, (CR8R8)qNR4C(O)R11, (CR8R8)qC(NR4)NR4R5, (CR8R8)qNR4C(NR5)R11, (CR8R8)qNHS(O)tR13, (CR8R8)qS(O)tNR4R5, or two R1 moieties together may form O-(CH2)sO or a 5 to 6 membered optionally saturated ring, and wherein the alkyl, aryl, arylalkyl, heteroaryl, heterocyclic moieties may be optionally substituted; Y is hydrogen, halogen, nitro, cyano, haloalkylalkyl, alkenyl, alkoxy, haloalkoxy, azide, (CR8R8)qS(O)tRa, (CR8R8)qORa, hydroxy, hydroxyalkyl, aryl, arylalkyl, arylalkenyl, aryloxy, arylalkyloxy, heteroaryl, heteroarylalkyl, heteroarylalkenyl, heteroaryl alkyloxy, heterocyclic, heterocyclic-alkyl, heterocyclic-alkyloxy, heterocyclic-alkenyl, (CR8R8)qNR4R5, alkenyl-C(O)NR4R5, (CR8R8)qC(O)NR4R5, (CR8R8)qC(O)NR4R10, S(O)3R8, (CR8R8)qC(O)R11, alkenylC(O)R11, (CR8R8)qC(O)OR11, alkenylC(O)OR11, (CR8R8)qOC(O)R11, (CR8R8)qNR4C(O)R11, (CR8R8)qNHS(O)tR13, (CR8R8)qS(O)tNR4R5, (CR8R8)qC(NR4)R5, (CR8R8)qNR4C(NR5)R11, or two Y moieties together may form O- (CH2)s-O or a 5 to 6 membered optionally saturated ring, and wherein the alkyl, aryl, arylalkyl, heteroaryl, heteroaryl alkyl, heterocyclic, heterocyclicalkyl groups may be optionally substituted; Ra, R4 to R8 are as defined in the specification; m is 1 to 3; n is 1 to 3; q is 0 to 10; t is 0 to 2 and s 1 to 3. The compounds are useful in treating a chemokine mediated disease, wherein the chemokine binds to an IL-8 a or b receptor. |